Testing a diabetes drug for weight loss in MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MS and your condition has been stable for at least 12 months, meaning no relapses or new brain lesions on MRI.
- You are between 18 and 60 years old.
- Your body mass index (BMI) is 27 or higher.
- You have not taken GLP-1 or related drugs in the past year.
- You do not have certain stomach, pancreas, or thyroid problems, and you have no history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
- You are not pregnant, breastfeeding, or planning pregnancy; if you can become pregnant, you agree to reliable birth control.
- Your neurologist and the study team agree that you are a good candidate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.
This study tests a new medicine (NNC6989-0001) for people who are overweight or have obesity. It checks if the medicine is safe and how the body handles it. If eligible, you would receive the study drug and be monitored closely.
This study tests an investigational medicine to help people who have lost weight keep it off. It's for adults without diabetes who haven't used similar weight-loss drugs before.
This study tests whether a new medicine called NNC0487-0111 helps people with type 2 diabetes and excess weight lose weight. You'll take the medicine along with your current diabetes care to see if it works better than standard treatment.
This trial tests an experimental drug called GS-4571 in three groups: healthy individuals, people with obesity (but not diabetes), and people with type 2 diabetes who are not obese. The study aims to see how the drug affects the body and how safe it is.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.